Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|November 18, 2020
EMA Raises Antibiotic Use Awareness
Author(s)Pharmaceutical Technology Editors
The agency marked the annual European Antibiotic Awareness Day with the launch of a social media campaign highlighting the prudent use of antibiotics.
Advertisement
The European Medicines Agency (EMA) announced on Nov. 18, 2020 that it is launching a social media campaign to stress the importance of prudent use of antibiotics. The campaign is part of the agency’s recognition of European Antibiotic Awareness Day, the European Union’s initiative to raise awareness about antimicrobial resistance.
The campaign includes info-cards on what the pharmaceutical industry, the public, healthcare professionals, and the media can do to ensure that antibiotics are used wisely. Because bacteria and microorganisms can change over time and develop resistance to antibiotics, EMA says that prudent use of such treatments may help slow that process.
“Tackling antimicrobial resistance is a global challenge and a high priority for EMA and the European medicines regulatory network. We all have a role to play in addressing this challenge: regulators, governments, companies through development of new innovative antibiotics, but also healthcare professionals and patients by making sure they prescribe and use antibiotics wisely and responsibly,” said Emer Cooke, EMA’s executive director, in a
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement